Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC
To observe and evaluate the efficacy and safety of irinotecan liposome (II) combined with 5-fluorouracil(5-FU), calcium leucovorin(LV), and bevacizumab in the treatment of metastatic colorectal cancer.
Colorectal Neoplasms Malignant
DRUG: Irinotecan liposome (ll) + 5-FU/LV + bevacizumab
Objective response rate (ORR), Investigator-assessed 2-month objective response rate (ORR) : proportion of subjects achieving a complete response (CR) or partial response (PR) in the analysis population according to RECIST v1.1 criteria 2 months after patient administration., 2 months after patient administration
Disease Control Rate (DCR), Investigator-evaluated 2-month disease control rate (DCR): the proportion of subjects in the analysis population who achieved CR, PR or stable disease (SD) according to RECIST v1.1 criteria 2 months after patients administration, 2 months after patients administration|Treatment-related adverse events, Evaluating the Safety of Investigational Drugs by NCI-CTC AE Version 5.0 Criteria, 2 months after patient administration
Subjects enter the screening period after being fully informed and signing an informed consent form. The screening period for the study is 28 days. After completing the screening inspection and evaluation, the selected subjects receive irinotecan liposome (II) combined with 5-FU/LV and bevacizumab treatment, a total of 4 anti-tumor treatment cycles were observed. After the 4 cycles of treatment, the next step of treatment was jointly decided after the evaluation of the researcher and the consideration of the patient's personal treatment wishes.